Author:
Wang Xingtong,Guo Wei,Shi Xiaoju,Chen Yujia,Yu Youxi,Du Beibei,Tan Min,Tong Li,Wang Anna,Yin Xianying,Guo Jing,Martin Robert C.,Bai Ou,Li Yan
Abstract
Abstract
Background
Excess body weight has been found to associate with an increased risk of lymphomas and some metabolic pathways are currently recognized in lymphomagenesis. Bioactive lipid metabolites such as sphingosine-1-phosphate (S1P) have been proposed to play an important role linking obesity and lymphomas. However, the underlying mechanism(s) of S1P signaling in obesity-lymphomagenesis have not been well addressed.
Methods
The gene expression of sphingosine kinase (SPHK), lymphoma prognosis, and S1P production were analyzed using Gene Expression Omnibus (GEO) and human lymphoma tissue array. Obesity-lymphoma mouse models and lymphoma cell lines were used to investigate the S1P/SPHK-YAP axis contributing to obesity-lymphomagenesis. By using the mouse models and a monocyte cell line, S1P-mediated polarization of macrophages in the tumor microenvironment were investigated.
Results
In human study, up-regulated S1P/SPHK1 was found in human lymphomas, while obesity negatively impacted progression-free survival and overall survival in lymphoma patients. In animal study, obesity-lymphoma mice showed an aggressive tumor growth pattern. Both in vivo and in vitro data suggested the existence of S1P-YAP axis in lymphoma cells, while the S1P-ALOX15 signaling mediated macrophage polarization towards TAMs exacerbated the lymphomagenesis. In addition, treatment with resveratrol in obesity-lymphoma mice showed profound effects of anti-lymphomagenesis, via down-regulating S1P-YAP axis and modulating polarization of macrophages.
Conclusion
S1P/S1PR initiated the feedback loops, whereby S1P-S1PR1/S1PR3-YAP signaling mediated lymphomagenesis contributing to tumor aggressive growth, while S1P-ALOX15 signaling mediated TAMs contributing to immunosuppressive microenvironment in obesity-lymphoma. S1P-targeted therapy could be potentially effective and immune-enhancive against obesity-lymphomagenesis.
Graphical Abstract
Funder
Research reported in this publication was supported partly by Department of Finance of Jilin Province
Publisher
Springer Science and Business Media LLC
Reference64 articles.
1. Organization WH. 2022 https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight#:~:text=Of%20these%20over%20650%20million,overweight%20or%20obese%20in%202020.
2. Mili N, Paschou SA, Goulis DG, Dimopoulos MA, Lambrinoudaki I, Psaltopoulou T. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021;74(3):478–97. https://doi.org/10.1007/s12020-021-02884-x.
3. Scully T, Ettela A, LeRoith D, Gallagher EJ. Obesity, type 2 diabetes, and Cancer risk. Front Oncol. 2020;10:615375. https://doi.org/10.3389/fonc.2020.615375.
4. Lega IC, Lipscombe LL. Review: diabetes, obesity, and Cancer-pathophysiology and clinical implications. Endocr Rev. 2020;41(1). https://doi.org/10.1210/endrev/bnz014.
5. Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018;6(6):e6–e15. https://doi.org/10.1016/S2213-8587(18)30150-5.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献